Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05041153
Title Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center

gastroesophageal adenocarcinoma

gastric adenocarcinoma


Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.